EL7.AI
StocksMedium•6 November 2026•
1 min read

iRhythm Shares Hit 52-Week Low on Q3 Miss and Zio MCT FDA Delay

Key Facts

1iRhythm reported a Q3 adjusted EPS of -$0.90, missing analyst forecasts by $0.95.
2The CEO announced that the FDA filing for the Zio MCT device has been delayed until 2027.
3The company's shares hit a new 52-week low following the earnings release.

iRhythm reported a Q3 2026 adjusted EPS of -$0.90, missing analyst forecasts by $0.95 according to TradingView. CEO Quentin Blackford announced that the company has delayed its FDA filing for the Zio MCT device until 2027, shifting from the previous plan to submit it later this year. Following the earnings release and the regulatory delay, the company's shares plummeted to a new 52-week low.

Revenue for the quarter reached $221.6 million, missing Street forecasts by $0.6 million. Quentin Blackford stated that the decision to delay the Zio MCT filing allows the company to focus on integrating a product acquired through the recent Vital Connect buyout. Despite the quarterly miss, iRhythm revised its full-year 2026 revenue outlook upward to a range of $890 million to $895 million.